Mersana Therapeutics, Inc.

As of May 9, 2022, Mersana Therapeutics, Inc. is considered risky and overvalued, with key ratios indicating significant concerns, as evidenced by a year-to-date return of -79.44% compared to the S&P 500's positive return of 12.22%.

As of May 9, 2022, Mersana Therapeutics, Inc. is classified as risky and overvalued due to concerning financial ratios, a significant year-to-date stock price decline of 76.18%, and poor performance compared to peers like Stoke Therapeutics, Inc. and Harpoon Therapeutics, Inc.

As of May 16, 2025, the technical trend is mildly bearish, influenced by daily moving averages and weekly Bollinger Bands indicating bearish momentum, despite some mildly bullish signals from the MACD and mixed trends according to Dow Theory.

As of March 2022, Mersana Therapeutics, Inc.'s management team includes Mr. David Mott as Independent Chairman and Ms. Anna Protopapas as President and CEO, along with several Independent Directors on the Board.

Mersana Therapeutics, Inc. is a biotechnology company specializing in the development of antibody drug conjugates (ADCs). As of March 2025, it reported net sales of $3 million and a net loss of $24 million, with a market cap of $44.04 million.

As of Jun 18, Mersana Therapeutics, Inc. has a market capitalization of 44.04 million and reported net sales of 34.00 million, with a net profit of -74.01 million. The company has shareholder's funds of -9.51 million and total assets of 144.66 million.